Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for atherosclerosis progression in adults with impaired glucose tolerance
ChiCTR2200063693Phase 4Not yet recruiting
- Sponsor
- Qingdao Chengyang District People's Hospital
- Start
- Sep 2022
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of liraglutide in prediabetes and atherosclerosis (2 arms), sponsored by Qingdao Chengyang District People's Hospital. Primary endpoints: blood glucose, insulin and 10 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
03
Conditions
prediabetesatherosclerosis
Beyond the preview
Go deeper on ChiCTR2200063693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063693.